Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
April 29 2021 - 8:00AM
Business Wire
- Data to be Presented Highlight Significant
Progress Across Several Tumor Types -
Seagen Inc. (Nasdaq:SGEN) today announced the presentation of
new data from its growing pipeline of marketed and investigational
therapies at the virtual scientific program of the 2021 American
Society of Clinical Oncology (ASCO) Annual Meeting, to be held June
4-8.
“Emerging data and the breadth of our clinical development
programs continue to illustrate progress across our oncology
portfolio, highlighting the company’s research efforts in multiple
cancers with a high unmet need,” said Roger Dansey, M.D., Chief
Medical Officer at Seagen. “Notably, we are looking forward to
sharing updated results of the EV-103 and EV-201 clinical trials
for PADCEV® (enfortumab vedotin-ejfv) in locally advanced or
metastatic urothelial cancer and additional data from the HER2CLIMB
trial of TUKYSA® (tucatinib) in previously treated HER2+ metastatic
breast cancer patients.”
Key data to be presented include:
Abstract Title
Abstract #
Presentation type
Lead Author
PADCEV® (enfortumab
vedotin-ejfv)
Study EV-103: Update on durability results
and long-term outcome of enfortumab vedotin + pembrolizumab in
first line locally advanced or metastatic urothelial carcinoma
(la/mUC)
4528
Poster Presentation
T. Friedlander
Enfortumab vedotin in cisplatin-ineligible
patients with locally advanced or metastatic urothelial cancer who
received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201
Cohort 2
4524
Poster Presentation
B. McGregor
Quality of life, functioning, and symptoms
in patients with previously treated locally advanced or metastatic
urothelial carcinoma from EV-301: A randomized Phase 3 trial of
enfortumab vedotin vs chemotherapy
4539
Poster Presentation
R. Mamtani
KEYNOTE-B15/EV-304: Randomized Phase 3
study of perioperative enfortumab vedotin plus pembrolizumab versus
chemotherapy in cisplatin-eligible patients with muscle-invasive
bladder cancer (MIBC)
TPS4587
Poster Presentation
C. Hoimes
TUKYSA® (tucatinib)
Updated results of tucatinib vs placebo
added to trastuzumab and capecitabine for patients with pretreated
HER2+ metastatic breast cancer with and without brain metastases
(HER2CLIMB)
1043
Poster Presentation
G. Curigliano
Pharmacokinetic (PK) analyses in CSF and
plasma from TBCRC049, an ongoing trial to assess the safety and
efficacy of the combination of tucatinib, trastuzumab and
capecitabine for the treatment of leptomeningeal metastasis (LM) in
HER2 positive breast cancer
1044
Poster Presentation
E. Stringer-Reasor
SGNTUC-019: Phase 2 basket study of
tucatinib and trastuzumab in previously treated solid tumors with
HER2 alterations (trial in progress)
TPS3151
Poster Presentation
T. Stinchcombe
HER2CLIMB-04: Phase 2 open label trial of
tucatinib plus trastuzumab deruxtecan in patients with HER2+
unresectable locally advanced or metastatic breast cancer with and
without brain metastases (trial in progress)
TPS1097
Poster Presentation
I. Krop
A011801 (CompassHER2 RD): Postneoadjuvant
T-DM1 + tucatinib/placebo in patients with residual HER2-positive
invasive breast cancer
TPS595
Poster Presentation
C. O’Sullivan
ADCETRIS® (brentuximab
vedotin)
Brentuximab vedotin with chemotherapy in
adolescents and young adults (AYAs) with stage III or IV Hodgkin
lymphoma: A subgroup analysis from the Phase 3 Echelon-1 study
7528
Poster Presentation
H. Crosswell
Brentuximab vedotin in combination with
lenalidomide and rituximab in subjects with relapsed or refractory
diffuse large B-cell lymphoma (DLBCL) (trial in progress)
TPS7571
Poster Presentation
N. Bartlett
Tisotumab vedotin
Tisotumab vedotin vs investigator’s choice
chemotherapy in second- or third-Line recurrent or metastatic
cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in
progress)
TPS5596
Poster Presentation
I. Vergote
Early Pipeline
SGNTGT-001: A Phase 1 study of SEA-TGT, an
effector-function enhanced monoclonal antibody (mAb), in advanced
malignancies (trial in progress)
TPS2657
Poster Presentation
E. Garralda
A Phase 1 study of SGN-B6A, an
antibody-drug conjugate targeting Integrin beta-6, in patients with
advanced solid tumors (SGNB6A-001, trial in progress)
TPS3144
Poster Presentation
A. Patnaik
About Seagen
Seagen is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
the company’s marketed products and robust pipeline, visit
www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company’s
pipeline and the therapeutic potential of PADCEV, TUKYSA, ADCETRIS,
tisotumab vedotin, SEA-TGT and SGN-B6A, including their efficacy,
safety and potential therapeutic uses. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include without limitation the difficulty and
uncertainty of pharmaceutical product development, including the
risks that the company may experience delays in its clinical trials
or otherwise experience failures or setbacks in its clinical
development programs due to lack of efficacy, adverse events or
other factors, and that adverse regulatory actions may occur. More
information about the risks and uncertainties faced by Seagen is
contained under the caption “Risk Factors” included in the
company’s Annual Report on Form 10-K for the year ended December
31, 2020 filed with the Securities and Exchange Commission. Seagen
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005417/en/
Peggy Pinkston (425) 527-4160 ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024